Amarin shares slightly lower after FDA updates Orange Book Amarin shares are down 10c, or 1.15%, to $8.57 after an update in the FDA's Orange Book regarding the company's drug Vascepa said, "There is no unexpired exclusivity for this product." The FDA posting noted that the Orange Book Data was updated through January, 2013 and that patent and generic drug product data was last updated on February 19. Reference Link
News For AMRN From The Last 14 Days
Check below for free stories on AMRN the last two weeks.